183 related articles for article (PubMed ID: 20850528)
1. CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3+ regulatory T cells in the target tissue: kidney.
Zhang JL; Sun DJ; Hou CM; Wei YL; Li XY; Yu ZY; Feng JN; Shen BF; Li Y; Xiao H
Transpl Immunol; 2010 Oct; 24(1):17-25. PubMed ID: 20850528
[TBL] [Abstract][Full Text] [Related]
2. Anti-T cell receptor antibody treatment of mice with lupus-like graft versus host disease: suppression of glomerulonephritis without reduction in anti-DNA antibody levels.
Maeda T; Nomoto K
J Rheumatol; 1995 Dec; 22(12):2259-65. PubMed ID: 8835559
[TBL] [Abstract][Full Text] [Related]
3. ANTI-CD3 therapy expands the numbers of CD4+ and CD8+ Treg cells and induces sustained amelioration of collagen-induced arthritis.
Notley CA; McCann FE; Inglis JJ; Williams RO
Arthritis Rheum; 2010 Jan; 62(1):171-8. PubMed ID: 20039431
[TBL] [Abstract][Full Text] [Related]
4. Antroquinonol differentially modulates T cell activity and reduces interleukin-18 production, but enhances Nrf2 activation, in murine accelerated severe lupus nephritis.
Tsai PY; Ka SM; Chang JM; Lai JH; Dai MS; Jheng HL; Kuo MT; Chen P; Chen A
Arthritis Rheum; 2012 Jan; 64(1):232-42. PubMed ID: 21905011
[TBL] [Abstract][Full Text] [Related]
5. IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4
Yan JJ; Lee JG; Jang JY; Koo TY; Ahn C; Yang J
Kidney Int; 2017 Mar; 91(3):603-615. PubMed ID: 27914701
[TBL] [Abstract][Full Text] [Related]
6. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide.
Sharabi A; Lapter S; Mozes E
J Autoimmun; 2010 Mar; 34(2):87-95. PubMed ID: 19596183
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of DCB-SLE1, an extract of a mixture of Chinese medicinal herbs, for severe lupus nephritis.
Tsai PY; Ka SM; Chang JM; Chang WL; Huang YJ; Hung LM; Jheng HL; Wu RY; Chen A
Am J Physiol Renal Physiol; 2011 Oct; 301(4):F751-64. PubMed ID: 21677146
[TBL] [Abstract][Full Text] [Related]
9. The effects of Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody in DSS-induced mice colitis.
Chen J; Xie L; Toyama S; Hünig T; Takahara S; Li XK; Zhong L
Int Immunopharmacol; 2011 May; 11(5):610-7. PubMed ID: 21163250
[TBL] [Abstract][Full Text] [Related]
10. Reduction of Foxp3-expressing regulatory T cell infiltrates during the progression of renal allograft rejection in a mouse model.
Wang S; Jiang J; Guan Q; Lan Z; Wang H; Nguan CY; Jevnikar AM; Du C
Transpl Immunol; 2008 May; 19(2):93-102. PubMed ID: 18503884
[TBL] [Abstract][Full Text] [Related]
11. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
Steinmetz OM; Turner JE; Paust HJ; Lindner M; Peters A; Heiss K; Velden J; Hopfer H; Fehr S; Krieger T; Meyer-Schwesinger C; Meyer TN; Helmchen U; Mittrücker HW; Stahl RA; Panzer U
J Immunol; 2009 Oct; 183(7):4693-704. PubMed ID: 19734217
[TBL] [Abstract][Full Text] [Related]
12. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase.
Iwanami K; Matsumoto I; Tanaka-Watanabe Y; Inoue A; Mihara M; Ohsugi Y; Mamura M; Goto D; Ito S; Tsutsumi A; Kishimoto T; Sumida T
Arthritis Rheum; 2008 Mar; 58(3):754-63. PubMed ID: 18311788
[TBL] [Abstract][Full Text] [Related]
13. TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis.
Molano A; Lakhani P; Aran A; Burkly LC; Michaelson JS; Putterman C
Immunol Lett; 2009 Aug; 125(2):119-28. PubMed ID: 19573558
[TBL] [Abstract][Full Text] [Related]
14. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.
Liang B; Gardner DB; Griswold DE; Bugelski PJ; Song XY
Immunology; 2006 Nov; 119(3):296-305. PubMed ID: 17067309
[TBL] [Abstract][Full Text] [Related]
15. Characterization of reactivity of monoclonal autoantibodies with renal antigens in experimental lupus nephritis.
Kootstra JC; Veninga A; Baelde JJ; van Eendenburg J; de Heer E; Bruijn JA
J Clin Lab Immunol; 1996; 48(5):201-18. PubMed ID: 9394243
[TBL] [Abstract][Full Text] [Related]
16. Roquinimex-mediated protection effect on the development of chronic graft-versus-host disease in mice is associated with induction of Th1 cytokine production and inhibition of proinflammatory cytokine production.
Xiao ZY; Zhou WX; Zhang YX; Cheng JP; He JF; Yang RF; Yun LH
Life Sci; 2007 Oct; 81(19-20):1403-10. PubMed ID: 17950363
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function.
Kalled SL; Cutler AH; Datta SK; Thomas DW
J Immunol; 1998 Mar; 160(5):2158-65. PubMed ID: 9498753
[TBL] [Abstract][Full Text] [Related]
18. In vivo expansion of CD4+Foxp3+ regulatory T cells mediated by GITR molecules.
Nishioka T; Nishida E; Iida R; Morita A; Shimizu J
Immunol Lett; 2008 Dec; 121(2):97-104. PubMed ID: 18930767
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic MHC antigen requirements for lupus-like autoantibody production and nephritis in murine graft-vs-host disease.
Portanova JP; Ebling FM; Hammond WS; Hahn BH; Kotzin BL
J Immunol; 1988 Nov; 141(10):3370-6. PubMed ID: 3263424
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis.
Sfikakis PP; Souliotis VL; Fragiadaki KG; Moutsopoulos HM; Boletis JN; Theofilopoulos AN
Clin Immunol; 2007 Apr; 123(1):66-73. PubMed ID: 17275413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
